Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This observational study will observe the degree of the quality of life in patients with
multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and
EQ-5D (EuroQol-5 Dimensions). Both tools are validated research instruments used to measure
the quality of life in cancer patients and consequently will provide fundamental data
regarding the quality of life in patients with multiple myeloma by analyzing factors that
affect the quality of life.